Please login to the form below

Not currently logged in
Email:
Password:

Lonquex

This page shows the latest Lonquex news and features for those working in and with pharma, biotech and healthcare.

Cuts help Teva raise profits, despite flat sales

Cuts help Teva raise profits, despite flat sales

Teva's specialty medicines business also benefitted from the introduction of biosimilar filgrastim (G-CSF) products Lonquex and Granix, which have captured market share of around 10% in the markets they

Latest news

  • Teva withdraws US filing for cancer biologic Teva withdraws US filing for cancer biologic

    There was better news for Teva's G-CSF portfolio however after it launched its long-acting G-CSF product Lonquex (lipegfilgrastim) on November 4 in Germany, the first EU market

  • Neulasta rival from Teva cleared in EU Neulasta rival from Teva cleared in EU

    Neulasta rival from Teva cleared in EU. Lonquex offers competition to Amgen drug in neutropaenia. ... Lonquex is the first biologic medicine from Teva's branded medicines division to be approved for marketing.

  • EMA backs Pomalidomide Celgene in multiple myeloma EMA backs Pomalidomide Celgene in multiple myeloma

    Elsewhere, there were further recommendations for Teva's (Lonquex) lipegfilgrastim, which was recommended for the reduction in white blood cells of cancer patients on chemotherapy; Bavarian Nordic's smallpox vaccine Imnavex;

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics